
Opinion|Videos|February 4, 2025
Diagnositc Feasibility: Liquid Biopsy vs Tissue Biopsy for Diagnostic Testing
A panelist discusses how although liquid biopsy offers potential advantages in terms of convenience and repeatability, tissue biopsy remains the current standard for MAGE-A4 testing because of the need for accurate protein expression assessment and established validation protocols, though ongoing research may eventually support complementary use of liquid biopsy approaches.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What are your thoughts on the feasibility of using liquid biopsy vs tissue biopsy for diagnostic or eligibility testing?
Advertisement
Related to this article

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5

